CD8A and cancer: The combination of p-Tvax and the OX86 mAb modified the tumor microenvironment in a manner that led to more optimal anti-cancer immune conditions as supported by higher abundance of both CD8+ and CD4+ T cells, and reduced percentages of Tregs (Figure 5).